文献速递治疗药物监测与药物基因组学

异烟肼在肺结核中精准给药的模型引导方法

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.
PubMed 文献 · Clin Pharmacokinet · 2021-02-22

本研究基于七项研究、466例患者数据开发异烟肼群体药代动力学模型,并评估三种有限采样策略。含2和4小时采样的策略预测AUC24的ME为1.1%、RMSE为23.4%,峰浓度的ME为2.7%、RMSE为23.8%,被确定为最合适策略。

要点

  • 基于模型的治疗药物监测可采用给药后2和4小时采样预测异烟肼AUC24和峰浓度。
  • 该策略需同时使用异烟肼和乙酰异烟肼数据,预测偏差和精度可接受。
  • 若仅有异烟肼数据,可用2、4和6小时采样策略替代。

核心结论

  • 成功开发了基于模型的异烟肼个体化给药治疗药物监测策略,采用给药后2和4小时采样。

研究设计与样本

  • 基于七项研究、共466例来自三大洲患者的异烟肼和乙酰异烟肼药代动力学数据开发群体药代动力学模型。
  • 测试了三种有限采样策略:2、4和6小时,2和4小时,以及给药后2小时采样。

主要发现

  • 模型性能可接受,参数估计不确定性通常较低,最高相对标准误为39%变异系数。
  • 2和4小时采样策略预测AUC24的ME为1.1%、RMSE为23.4%,预测峰浓度的ME为2.7%、RMSE为23.8%。
  • 若仅有异烟肼数据,2、4和6小时采样策略预测AUC24的ME为1.7%、RMSE为20.9%,预测峰浓度的ME为1.2%、RMSE为23.8%。

关键数值与推荐

  • 最合适有限采样策略为给药后2和4小时采样,需同时使用异烟肼和乙酰异烟肼数据。
  • 仅有异烟肼数据时可使用2、4和6小时采样策略。

临床怎么用

  • 临床治疗药物监测中可采用给药后2和4小时采样,基于模型预测异烟肼AUC24和峰浓度以支持精准 dosing。
  • 实施时需确保同时获取异烟肼和乙酰异烟肼浓度数据。

局限性

  • 该策略尚需前瞻性评估以验证其在临床治疗药物监测 setting 中的表现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: This study aimed to develop and evaluate a population pharmacokinetic model and limited sampling strategy for isoniazid to be used in model-based therapeutic drug monitoring. METHODS: A population pharmacokinetic model was developed based on isoniazid and acetyl-isoniazid pharmacokinetic data from seven studies with in total 466 patients from three continents. Three limited sampling strategies were tested based on the available sampling times in the dataset and practical considerations. The tested limited sampling strategies sampled at 2, 4, and 6 h, 2 and 4 h, and 2 h after dosing. The model-predicted area under the concentration-time curve from 0 to 24 h (AUC24) and the peak concentration from the limited sampling strategies were compared to predictions using the full pharmacokinetic curve. Bias and precision were assessed using the mean error (ME) and the root mean square error (RMSE), both expressed as a percentage of the mean model-predicted AUC24 or peak concentration on the full pharmacokinetic curve. RESULTS: Performance of the developed model was acceptable and the uncertainty in parameter estimations was generally low (the highest relative standard error was 39% coefficient of variation). The limited sampling strategy with sampling at 2 and 4 h was determined as most suitable with an ME of 1.1% and RMSE of 23.4% for AUC24 prediction, and ME of 2.7% and RMSE of 23.8% for peak concentration prediction. For the performance of this strategy, it is important that data on both isoniazid and acetyl-isoniazid are used. If only data on isoniazid are available, a limited sampling strategy using 2, 4, and 6 h can be employed with an ME of 1.7% and RMSE of 20.9% for AUC24 prediction, and ME of 1.2% and RMSE of 23.8% for peak concentration prediction. CONCLUSIONS: A model-based therapeutic drug monitoring strategy for personalized dosing of isoniazid using sampling at 2 and 4 h after dosing was successfully developed. Prospective evaluation of this strategy will show how it performs in a clinical therapeutic drug monitoring setting.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. van Beek SW, Ter Heine R, Alffenaar JC, et al. A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. Clin Pharmacokinet. 2021. PMID: 33615419. doi:10.1007/s40262-020-00971-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。